Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV randomized open-label non-inferiority trial of intravenous colistin versus intravenous meropenem for ventilator-associated pneumonia
2010-023310-31Phase 4Completed
- Sponsor
- CAIBER
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP) comparing Intravenous colistimethate sodium with Intravenous meropenem (2 arms). Primary endpoint: 28-day mortality. Started Nov 2010; status: completed.
02
Drugs
colistimethate sodiummeropenem
03
Conditions
ventilator-associated pneumonia (VAP)hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on 2010-023310-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023310-31.